In a clinical study conducted on 11 patients, the authors reported that although the high affinity of this tracer for tau protein aggregates in vitro, it did not yield positive results in vivo and exhibited low brain retention in AD patients with mild cognitive impairment (MCI).375 [18F]PI-2620 is another potent agent currently in a phase III clinical trial. This evidence concerns the gene MAPT and Alzheimer disease.